Clinical trials: Vasomotor Symptoms Associated With Menopause
Vasomotor Symptoms Associated With Menopause, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the…
- Trial name
- OASIS-3 (NCT05030584)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 86 sites in United States, Belgium and 7 more
- Volunteers
- 628 people
- Sponsor
- Bayer
Menopause, Hot Flashes
Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
This study is aiming to evaluate changes in vasomotor symptoms in postmenopausal women treated for 4 months with Omega-3 vs Soy Isoflavones.
- Trial name
- OMEGASI (NCT02195609)
- Testing
- Omega-3, Soy Isoflavones
- Where
- Spain
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Instituto Palacios
Hot Flashes
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes.
- Trial name
- Starlight 2 (NCT06206408)
- Testing
- Fezolinetant
- Where
- 64 sites in Japan
- Volunteers
- 410 people
- Sponsor
- Astellas Pharma Inc
Hot Flashes
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 1 (NCT04003155)
- Testing
- fezolinetant
- Where
- 96 sites in United States, Canada and 5 more
- Volunteers
- 527 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Hot Flashes
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause
This study is for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Moonlight 1 (NCT04234204)
- Testing
- Fezolinetant
- Where
- 48 sites in China, South Korea and 1 more
- Volunteers
- 302 people
- Sponsor
- Astellas Pharma China, Inc.
Menopause, Hot Flashes
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of…
- Conditions
- Menopause, Hot Flashes, Sleep Disorders
- Trial name
- NCT00256685
- Testing
- DVS-233 SR
- Volunteers
- 568 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hot Flashes
A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause
This study is for women in menopause with hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Moonlight 3 (NCT04451226)
- Testing
- Fezolinetant
- Where
- 29 sites in China
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma China, Inc.
Hot Flashes
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes.
- Trial name
- NCT06812754
- Testing
- Fezolinetant
- Where
- 26 sites in China
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Menopause, Vasomotor Symptoms
A Survey About Hot Flashes in Women Going Through the Menopause
This study is an online survey of women in and around menopause with moderate to severe hot flashes. Menopause, a normal part of life, is a time after a woman's last period. Hot flashes often occur during menopause.
- Trial name
- NCT05083884
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 2,176 people
- Sponsor
- Astellas Pharma Europe Ltd.
Post-menopausal Vasomotor Symptoms
Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause
In this clinical research study, subjects will be given the study drug, ACER-801 (osanetant) or placebo (looks like the study drug but contains no active ingredients).
- Trial name
- NCT05325775
- Testing
- ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Acer Therapeutics Inc.
Menopause
A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-related Vasomotor Symptoms (MR-VMS)
The purpose of this study is to estimate the prevalence of Vasomotor Symptoms (VMS) and prevalence of moderate to severe VMS in peri-menopausal women and post-menopausal women aged 40-65 in East Asia (China, South Korea and…
- Trial name
- NCT04553029
- Testing
- No intervention
- Where
- 3 sites in China, South Korea and 1 more
- Volunteers
- 3,399 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Vasomotor Symptoms Associated With Menopause
Herbal Alternatives for Menopause Symptoms (HALT Study)
Surveys indicate that 25 to 33% of women have moderate to severe menopausal symptoms including hot flashes, night sweats, and disturbed sleep.
- Trial name
- NCT00169299
- Testing
- Black cohosh, Multibotanical preparation, Multibotanical preparation + dietary soy counseling
- Where
- United States
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Perimenopause, Perimenopause-Related Depression
Intra Ovarian Muse Cell Injection for Perimenopause Symptom Relief and Ovarian Function Restoration (MUSE-OVARY)
This observational study examines the safety and effects of injecting Muse cells (a type of naturally occurring stem like cells found in adult tissues such as fat or bone marrow) directly into the ovaries of women aged 28 to 70…
- Conditions
- Perimenopause, Perimenopause-Related Depression, Premature Ovarian Insufficiency, Premature Ovarian Failure (POF)
- Trial name
- MUSE-OVARY (NCT07511660)
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Healing Hope International
Depression, Menopause
Vortioxetine for Menopausal Depression
The broad goal of this study was to examine the efficacy and tolerability of vortioxetine (flexible dose) for the treatment of major depressive disorder (MDD) in symptomatic women around the menopausal transition.
- Conditions
- Depression, Menopause, Vasomotor Disturbance, Hot Flashes
- Trial name
- NCT02234362
- Testing
- vortioxetine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Massachusetts General Hospital
Hot Flashes
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause
- Trial name
- NCT01101841
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 32 sites in United States
- Volunteers
- 570 people
- Sponsor
- Noven Therapeutics
Postmenopausal Symptoms, Menopause
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
To investigate efficacy and safety of 4 doses of esmirtazapine, compared to placebo, in the treatment of moderate to severe hot flushes (vasomotor symptoms) associated with the menopause.
- Conditions
- Postmenopausal Symptoms, Menopause, Vasomotor Symptoms
- Trial name
- NCT00535288
- Testing
- Esmirtazapine
- Volunteers
- 946 people
- Sponsor
- Merck Sharp & Dohme LLC
Vasomotor Symptoms
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is a nonhormonal option for the treatment of Vasomotor Symptoms (VMS) associated with menopause.
- Trial name
- NCT00401245
- Testing
- desvenlafaxine succinate sustained release
- Where
- 74 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Pfizer
Severe Vasomotor Symptom Associated With Menopause
Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive
To evaluate safety and efficacy of CE/BZA in real practice in Korea
- Trial name
- NCT02792504
- Where
- 20 sites in South Korea
- Volunteers
- 669 people
- Sponsor
- Pfizer
Vasomotor Symptoms Associated With Menopause
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause.
- Trial name
- NCT00234819
- Testing
- Bazedoxifene/Conjugated Estrogen
- Where
- 7 sites in United States
- Volunteers
- 325 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hot Flashes
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice
This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS).
- Trial name
- CANDLELIGHT (NCT07602530)
- Testing
- Fezolinetant
- Where
- 2 sites in Canada
- Volunteers
- 238 people
- Sponsor
- Astellas Pharma Europe Ltd.